Exactly, and when it moves it can move fast. I got in a stock much like this at about $3.50 and once clinical test continued to look positive the stock ran to $45. When it comes to a cure for cancer anything can happen and there are no limits. At this point I wouldn't mind seeing a dip so I could get more shares at a lower price. Although if the stock does to $50 it won't much matter if I paid $2.10 or $1.80 will it? Not making any predictions but I believe the possibilities are overwhelming.
Remember that when someone tries to convince you to buy or sell there is something in it for them. It's not because they are concerned about your investment.
Recent MBRX News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 03/27/2026 08:01:09 PM
- Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout • GlobeNewswire Inc. • 03/23/2026 12:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 12:30:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 12:45:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/19/2026 12:35:12 PM
- Moleculin to Present at 38th Annual ROTH Conference • GlobeNewswire Inc. • 03/17/2026 01:05:00 PM
- Moleculin Releases Next CEO Corner Segment Highlighting MIRACLE Study • GlobeNewswire Inc. • 03/11/2026 01:00:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/09/2026 07:58:05 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/27/2026 07:09:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 01:50:23 PM
- Moleculin shares slide sharply after warrant exercise deal • IH Market News • 02/19/2026 03:46:31 PM
- Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds • GlobeNewswire Inc. • 02/19/2026 01:39:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 09:31:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/18/2026 01:20:16 PM
- Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30) • GlobeNewswire Inc. • 02/18/2026 01:20:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 01:35:16 PM
- Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin • GlobeNewswire Inc. • 02/17/2026 01:35:00 PM
- Moleculin Launches CEO Corner Platform to Share Strategic Insights • GlobeNewswire Inc. • 02/13/2026 01:32:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2026 04:55:04 PM
- Moleculin to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial • GlobeNewswire Inc. • 02/05/2026 02:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/20/2026 01:00:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2026 01:55:12 PM
- Moleculin Reports Independent Assessment Confirms No Cardiotoxicity of Annamycin in 90 Subjects • GlobeNewswire Inc. • 01/13/2026 01:55:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/12/2026 01:36:11 PM
- Moleculin Accelerates Outlook Into 2026 With First Pivotal Trial Unblinding on Track, Global Trial Expansion, and Multiple Externally/IIT Funded Clinical Programs • GlobeNewswire Inc. • 01/12/2026 01:36:00 PM
